To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity

Direct-acting antiviral agents have proven highly effective at treating existing hepatitis C infections but despite their availability most countries will not reach the World Health Organization targets for elimination of HCV by 2030. A prophylactic vaccine remains a high priority. Whilst early vacc...

Full description

Saved in:
Bibliographic Details
Published inViruses Vol. 13; no. 5; p. 805
Main Authors Schlotthauer, Felicia, McGregor, Joey, Drummer, Heidi E
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 30.04.2021
MDPI
Subjects
Antiviral agents
Binding sites
glycoprotein E2
Glycoproteins
Hepatitis C
Humoral immunity
Infections
Lymphocytes T
Monoclonal antibodies
Proteins
Review
Vaccine development
Vaccines
Viruses
vaccine development
glycoprotein E2
humoral immunity
Online AccessGet full text

Cover

More Information
Summary:Direct-acting antiviral agents have proven highly effective at treating existing hepatitis C infections but despite their availability most countries will not reach the World Health Organization targets for elimination of HCV by 2030. A prophylactic vaccine remains a high priority. Whilst early vaccines focused largely on generating T cell immunity, attention is now aimed at vaccines that generate humoral immunity, either alone or in combination with T cell-based vaccines. High-resolution structures of hepatitis C viral glycoproteins and their interaction with monoclonal antibodies isolated from both cleared and chronically infected people, together with advances in vaccine technologies, provide new avenues for vaccine development.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
These authors contributed equally to this work.
ISSN:1999-4915
1999-4915
DOI:10.3390/v13050805